Background-Accumulated data suggest that low-dose aspirin after myocardial infarction (MI) may offer similar efficacy to higher dose aspirin with reduced risk of bleeding. Few data are available on contemporary aspirin dosing patterns after MI in the United States Methods and Results-Aspirin dosing from 221 199 patients with MI (40.2% ST-segment-elevation MI) from 525 US hospitals enrolled in the National Cardiovascular Data Registry's (NCDR's) Acute Coronary Treatment and Intervention Outcomes Network Registry-Get with the Guidelines were described, overall and in clinically relevant subgroups. Highdose aspirin was defined as 325 mg and low dose as 81 mg. Between January 2007 and March 2011, 60.9% of patients with acute MI were discharged on high-dose aspirin, 35.6% on low-dose aspirin, and 3.5% on other doses. High-dose aspirin was prescribed at discharge to 73.0% of patients treated with percutaneous coronary intervention and 44.6% of patients managed medically. Among 9075 patients discharged on aspirin, thienopyridine, and warfarin, 44.0% were prescribed high-dose aspirin. Patients with an in-hospital major bleeding event were also frequently discharged on high-dose aspirin (56.7%).
A lthough the effectiveness of aspirin for secondary prevention after myocardial infarction (MI) is well established, the optimal daily dose of aspirin has been less clear. Aspirin dosing varies worldwide, with low-dose aspirin being preferred outside of the United States, 1 whereas US guidelines have historically viewed higher doses of aspirin more favorably. However, US guidelines regarding aspirin dosing following MI have recently changed, 2,3 based on randomized and observational studies suggesting similar efficacy of low-dose versus high-dose aspirin, with a reduced risk of bleeding. [4] [5] [6] These data and guidelines indicate a strong preference for low-dose as compared with high-dose aspirin after MI. There are no recent studies evaluating temporal changes in aspirin dosing for acute MI in the United States, and contemporary data on patterns of aspirin dosing are needed to better understand the implications of new recommendations for aspirin dosing after MI. Using data from the National Cardiovascular Data Registry's (NCDR's) Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get with the Guidelines (GWTG), we performed an evaluation of current practice regarding aspirin dose in the United States and identified patient-and hospital-level factors associated with variation in aspirin dose.
Methods
The ACTION Registry-GWTG, a large national quality improvement registry, collects data on consecutive hospitalized patients at participating centers with both ST-segment-elevation MI and non-STsegment-elevation MI. Trained hospital personnel from participating centers across the United States collect data from the medical record using standardized data definitions, as previously reported. 7 Abstracted data include patient demographics, clinical information, medical therapies, use and timing of cardiac procedures, and in-hospital outcomes. Patient confidentiality is protected with the removal of all identifiers before their use for research and through oversight by the Duke Clinical Research Institute analytic center's institutional review board.
Study Population
We included all 243 953 patients with acute MI from 603 participating centers across the United States who were enrolled into the registry between January 2, 2007, and March 31, 2011, were discharged from the original presenting center and were prescribed aspirin at discharge. We then excluded patients whose data were collected on the short data collection form that did not capture information on aspirin dosing (n=17 929), those with missing aspirin dose at discharge (n=1362), or those discharged on comfort care measures or to hospice (n=3463), leaving a cohort of 221 199 patients for the discharge aspirin dose prevalence analysis. Those patients who were discharged with aspirin doses other than 81 mg or 325 mg (n=7855; 3.5%) were subsequently excluded from all additional analyses, leaving 213 344 patients (40% ST-segment-elevation MI, 60% non-ST-segment-elevation MI) from 525 centers as the cohort for the remaining patientlevel analyses (Figure 1 ). To obtain stable hospital-level estimates, hospitals reporting data for fewer than 25 patients (61 sites) were excluded from hospital-level analyses.
Definitions
High-dose aspirin was defined as 325 mg and low dose as 81 mg. Triple therapy was defined as being prescribed concurrent aspirin, warfarin, and a thienopyridine at discharge. Major bleeding was defined according to the standard ACTION definition: an absolute hemoglobin drop of ≥4 g/dL (baseline to nadir), intracranial hemorrhage, documented or suspected retroperitoneal bleed, or any red blood cell transfusion in patients with a baseline hemoglobin ≥9 g/ dL or a clinically suspected bleeding event. Bleeding in patients who underwent coronary artery bypass graft (CABG) surgery during the index hospitalization was included only if it occurred before surgery. Hospital acute MI adherence score was defined as a hospital-level variable comprising the average use of aspirin, β-blocker, statin, angiotensin-converting enzyme/angiotensin receptor blocker, smoking cessation, and cardiac rehabilitation referral among patients with a class I indication for these therapies according to US practice guidelines 2,3 and without documented contraindication.
Statistical Analysis
Statistical analyses were performed at the Duke Clinical Research Institute in Durham, NC. P values were based on Pearson χ 2 tests for categorical variables, and Wilcoxon rank-sum test for continuous variables. Patient-level analyses were constructed using aspirin dosing overall, by type of revascularization, and by type of concurrent antiplatelet/ anticoagulation therapy. Hospital-level analyses included aspirin dosing overall and stratified by performance of percutaneous coronary intervention (PCI). Spearman correlation coefficients for the relationship between hospital performance score, calculated as the sum of a hospital's correctly provided care out of the total number of care opportunities encountered by the hospital in treating its patients with MI, and high-dose aspirin use were determined overall and stratified by PCI status. Factors associated with high-dose aspirin at discharge (versus low-dose aspirin) were explored using a hierarchical logistical model with hospital as the random effect. In a sensitivity analysis, the same outcome was fitted using a logistic model with hospital as fixed effect. For modeling, missing categorical variables for covariates were imputed to the most frequent value; missing ages were imputed to the median of nonmissing values, and missing weights were imputed to sex-specific medians.
Results
The distribution of aspirin dosing at discharge was 325 mg (60.9%), 81 mg (35.6%), and other doses (3.5%). Compared with patients discharged on low-dose aspirin, those discharged with high-dose aspirin were younger and more commonly male and were less likely to have atrial fibrillation, a history of congestive heart failure, stroke, peripheral arterial disease, diabetes mellitus, or hypertension ( Table 1 ). In contrast,
WHAT IS KNOWN
• Aspirin is effective for secondary prevention following acute myocardial infarction (MI), but dosing patterns across the United States are not well understood. • Clinical trial evidence supports a more favorable risk/benefit profile for lower doses of aspirin after MI as opposed to higher doses; current practice guidelines recommend low-dose aspirin as the preferred dose after MI.
WHAT THE STUDY ADDS
• High-dose aspirin use was common not only in patients with MI receiving intracoronary stents, but also in patients managed medically, those with significant in-hospital bleeding events, and those treated with concurrent clopidogrel and warfarin. • There was a 25-fold variation in the proportion of patients discharged on high-dose aspirin across study hospitals, suggesting local practice patterns may be a dominant influence on dosing decisions. • These findings suggest that large-scale educational efforts are needed to change US practice patterns regarding aspirin dosing post-MI. patients discharged on high-dose aspirin were more likely to have reported recent tobacco use. There were no significant temporal differences in the proportion of patients discharged on high-dose aspirin during the 4-year study period ( Figure 2 ).
Prevalence of High-Dose Aspirin Use in Subgroups Defined by In-Hospital Treatments, Complications, and Discharge Medications
Among subgroups defined by revascularization strategy, patients receiving PCI, with either drug-eluting or bare metal stent, had the highest prevalence of high-dose aspirin at discharge (73.7% and 73.0%, respectively; Table 2 ). In contrast, 44.6% of patients managed without revascularization and 47.8% of those who underwent CABG were discharged on high-dose aspirin. Almost half (48.4%) of patients who received a blood transfusion and more than half (56.7%) of those who had major bleeding were discharged on high-dose aspirin. High-dose aspirin was administered to 50.8% of patients discharged on aspirin alone, 68.6% of those prescribed aspirin and clopidogrel, and 26.0% of those prescribed aspirin and warfarin. Of the 9075 patients discharged on triple therapy, 44.0% were discharged with high-dose aspirin.
Factors Associated With High-Dose Aspirin Dosing
In a multivariable hierarchical model, we observed that PCI (including percutaneous transluminal coronary angioplasty alone, bare metal stent, and drug-eluting stent) was strongly associated with the high-dose aspirin use at discharge (Table 3 ). Younger age, male sex, smoking, and presentation with ST-segment-elevation MI (versus non-ST-segment-elevation MI) were also associated with a greater likelihood of high-dose aspirin use at discharge, although the magnitude of these associations was modest. In contrast, concurrent thienopyridine, warfarin, or thienopyridine plus warfarin use were all associated with a lower likelihood of high-dose aspirin use compared with aspirin alone. Having a history of diabetes mellitus, congestive heart failure, or peripheral arterial disease was also associated with a lower likelihood of high-dose aspirin use at discharge. Sensitivity analysis with hospital as fixed effect gave similar result (data not shown). Most variables have <0.8% missing. Although single imputation could modestly under-represent the uncertainty of the missing values, this effect should be minimal given the paucity of missing data.
Hospital-Level Analyses
We observed a 25-fold variance among hospitals in the proportion of patients discharged on high-dose aspirin, with some hospitals discharging <10% of patients on high-dose aspirin and other hospitals discharging 100% of patients on highdose aspirin. When stratified by PCI (Figure 3 ), the distribution curve of high-dose aspirin use was shifted to the right (high-dose aspirin use was higher overall) compared with the distribution among medically treated patients; however, for both subgroups, there was still considerable variation across hospitals in use of high-dose aspirin at discharge (range, 0%-100%). A modest but statistically significant association was observed between the proportion of high-dose aspirin use at discharge and hospital performance scores, with higher performing hospitals using more high-dose aspirin (Spearman correlation, 0.21; P<0.0001). In analyses restricted to Categorical variables were presented as frequency (percentage) of patients, whereas continuous variables were presented as median (interquartile range). CABG indicates coronary artery bypass graft; and PCI, percutaneous coronary intervention.
*Troponin ratio=local laboratory baseline troponin I or T value/local laboratory upper limit of normal for the assay used.
patients treated with PCI, the association remained statistically significant (Spearman correlation, 0.14; P=0.008), although quantitatively modest. In patients not treated with PCI, however, where there were no specific guideline recommendations for high-dose aspirin, no association between hospital performance score and use of high-dose aspirin was observed (Spearman correlation, 0.08; P=0.09).
Discussion
The present study is the most comprehensive analysis of US practice patterns of aspirin dosing following MI. In this large national registry of consecutive patients from the United States with acute MI, we observed that (1) most patients from 2007 to 2011 were discharged on high-dose aspirin; (2) high-dose aspirin use was common even among patients treated without revascularization, those with a major bleeding event during the index hospitalization, and those prescribed triple therapy;
(3) paradoxically, the majority of CABG patients were treated with low-dose aspirin, despite guidelines to the contrary; and (4) there was a 25-fold variation across participating centers in proportional use of high-dose aspirin.
Data to Support Lower Aspirin Dosing Recommendations
Observational analyses performed using data from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial demonstrated no significant difference in efficacy for low-dose aspirin (≤100 mg) versus high-dose aspirin (≥200 mg), 5 but an increase in bleeding complications with high-dose aspirin. Findings were similar among patients prescribed aspirin monotherapy versus dual antiplatelet treatment with aspirin and clopidogrel. The results of the Double-dose versus Standard-dose Clopidogrel and High-dose versus Low-dose Aspirin in Individuals undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes (CUR-RENT-OASIS 7) trial revealed no significant differences in major adverse cardiac events between patients with acute coronary syndrome randomized to high (300-325 mg) versus low-dose (75-100 mg) aspirin. 4 Although overall bleeding complications were not significantly different between the 2 aspirin groups, there was a higher incidence of gastrointestinal bleeding with high-dose aspirin compared with low-dose aspirin. Similarly, in the older Antithrombotic Trialists' metaanalysis, high-dose aspirin was associated with increased gastrointestinal and extracranial bleeding but no improvement in efficacy. 6 Together, these data suggest that low-dose aspirin is safer and provides similar efficacy versus high-dose aspirin. 
Contemporary Guideline Recommendations
Previous US guidelines recommended high-dose aspirin at discharge for patients receiving intracoronary stents, 8, 9 a recommendation that was not evidence based but rather reflected the study protocols from the early pivotal stent trials. 10, 11 These guideline recommendations were likely a major contributor to the practice pattern we observed during the study period. This recommendation has recently changed across all US guidelines, including ST-segment-elevation MI, unstable angina/non-STsegment-elevation MI, and PCI guidelines, 2,3,12 largely attributable to the results described above from CURRENT-OASIS 7. Each of these US guidelines now has a class IIa recommendation favoring 81 mg of aspirin over higher dosages. Interestingly, European Society of Cardiology guidelines in effect both before and throughout the present study's enrollment period recommended an aspirin maintenance dose of 75 to 100 mg in patients with MI, regardless of the type of intervention received (European Society of Cardiology class 1A), citing that lower doses of aspirin have the same efficacy as higher doses and carry a lower risk of gastrointestinal intolerance. 13 Despite the fact that post-CABG treatment is among the only cardiovascular situations where high-dose aspirin continues to be endorsed by guidelines (100-325 mg daily, class 1A), 14 patients undergoing CABG in the present study were paradoxically more likely to be discharged on low-dose rather than high-dose aspirin. Although aspirin dosing recommendations in the CABG guidelines are based predominantly on studies demonstrating improved saphenous vein graft patency in post-CABG patients treated with aspirin, [15] [16] [17] no direct comparative data exist in this context for high-versus low-dose aspirin.
Impact of Bleeding Risk on Aspirin Dosing
Although newer and more potent antiplatelet regimens reduce ischemic events, they also increase risk of bleeding. 18 Significant variables included in model listed above. Nonsignificant variables discarded during model selection include race, ST-segment changes (vs no ST-segment changes), CHF and shock at presentation, hypertension, prior stroke, diabetes mellitus, peripheral artery disease, prior clopidogrel, β-blocker, angiotensin-converting enzyme inhibitor, aldosterone-blocking agent, statin, nonstatin lipid-lowering agent, insurance, hospital region, and teaching hospital. CABG indicates coronary artery bypass graft; CHF, congestive heart failure; CI, confidence interval; MI, myocardial infarction; NSTEMI, non-ST-segment-elevation myocardial infarction; OR, odds ratio; PCI, percutaneous intervention; PTCA, percutaneous transluminal coronary angioplasty; SBP, systolic blood pressure; STEMI, ST-segment-elevation myocardial infarction; triple therapy, aspirin plus warfarin plus thienopyridine; and ULN, upper limit of normal.
*Vs medical management. †Vs aspirin alone. ‡Vs no services.
Bleeding following acute coronary syndrome is associated with increased morbidity and mortality, 19 and bleeding avoidance strategies are recommended in patients at high bleeding risk. However, in the present study reflecting contemporary US practice patterns, bleeding risk seemed to only modestly influence aspirin dosing, as nearly half of patients on triple therapy were discharged on high-dose aspirin, despite results from several observational studies demonstrating the association between triple therapy and as much as a 4-fold increased odds for bleeding. [20] [21] [22] Similarly, even patients with in-hospital major bleeding events were discharged with prescription for high-dose aspirin in >50% of cases.
Factors Influencing Aspirin Dosing
In patient-level analyses, stent placement was independently associated with high-dose aspirin use in multivariable analyses, an observation in accord with PCI guidelines at the time. Our hospital-level analyses further suggest that local and institutional practice habits play a substantial role in high-dose aspirin use, with surprisingly large variation in aspirin dosing across hospitals. When analyzed according to a hospital performance score, high-dose aspirin was paradoxically used more often in higher performing hospitals, although this comparison does not account for potential confounding. In patients not undergoing PCI, a subset where high-dose aspirin was not specifically guideline indicated, high-dose aspirin use at discharge remained high and varied widely across participating centers, perhaps suggesting a stronger influence of local practice habits in this setting. These findings suggest that local physician-or hospital-level practice habits, rather than individualized patient risk/benefit estimation, are the more important factors influencing aspirin prescribing patterns.
Limitations
The results of this analysis should be interpreted in context of several potentially important limitations. First, participation in the registry is voluntary. Participating centers tend to be larger, and tertiary care centers tend to be over-represented.
Care provided at participating centers may differ from that provided at nonparticipating centers. Second, only treatments and events occurring during the index hospitalization are captured, no information is available on clinical events or potential changes in aspirin dosing subsequent to hospital discharge. And third, data capture is performed retrospectively by trained chart abstractors using standardized definitions and is thus reliant on the accuracy of chart abstraction.
Implications
A substantial gap exists in the United States between the accumulated data, the most recent acute coronary syndrome and PCI US practice guidelines, and contemporary aspirin dosing patterns as described here. Simply stated, post-acute coronary syndrome patients should no longer be prescribed high-dose aspirin at discharge, regardless of the approach to PCI. Because the large majority of US patients are currently discharged on high-dose aspirin, major changes are required in US practice. Because a major influence of aspirin dosing seems to be hospital-level variation, an important target for rapid quality improvement will be redesigning hospital-based treatment pathways. Adding aspirin dosing to hospital-based quality reports, such as those from the ACTION Registry-GWTG, may be an important strategy to rapidly align practice patterns with the current evidence basis and guideline recommendations. Such changes would be expected to have favorable impact on bleeding complications in patients with MI. 
